SEC Form 4 · accession 0001062993-18-003670
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Gitman
Director
Period of report
Sep 7, 2018
Accepted (ET)
Sep 7, 2018 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value | Sep 7, 2018 | S | 1,000 | $57.637 | D | 20,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Remarks
The selling price of $57.6370 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $57.621 to $57.85. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.